Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2Daniel Watterson, Keith J. Chappell, Eve Radunz et al.|Clinical & Translational Immunology|2021Cited by 62
Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A virusesChristopher L. D. McMillan, Keith J. Chappell, Stacey T. M. Cheung et al.|npj Vaccines|2021Cited by 17
Molecular clamp stabilised Spike protein for protection against SARS-CoV-2Daniel Watterson, Keith J. Chappell, Danushka K. Wijesundara et al.|Unknown|2020Cited by 15
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J. Chappell, Trent P. Munro, Francesca L. Mordant et al.|EBioMedicine|2023Cited by 6
Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I TrialKeith J. Chappell, Daniel Watterson, Francesca L. Mordant et al.|The Journal of Infectious Diseases|2025Cited by 1